All In Biotech

Drug Trial Radar · NCT06290349

Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 174 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

174

Actual

Start

Apr 1, 2024

Primary completion

Sep 5, 2025

Study completion Mar 31, 2026

Sponsor

Lead sponsor
Dong-A ST Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the efficacy and safety of adding the SGLT-2 inhibitor DA5221-T to the combination therapy of DA5221-B1 and the DPP-4 inhibitor DA5221-B2 in patients with type 2 diabetes who have inadequate blood glucose control. The study focuses on assessing the effectiveness and safety of the triple combination therapy.

Conditions

  • Type 2 Diabetes

Interventions

  • DA5221-T1Drug

    DA5221-T1 + DA5221-R2, orally, once daily, up to 24 weeks

  • DA5221-T2Drug

    DA5221-R1 + DA5221-T2, orally, once daily, up to 24 weeks

  • PlaceboDrug

    DA5221-R1 + DA5221-R2, orally, once daily, up to 24 weeks

  • DA5221-B1Drug

    DA5221-B1, orally, daily for background therapy

  • DA5221-B2Drug

    DA5221-B2, orally, daily for background therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from the baseline in HbA1c (%) after 24 weeksTime frame: Baseline, 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital, Yonsei University college of Medicine

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.